Thomson Reuters Corporation: Thomson Reuters Empowers Drug Development and Clinical Professionals to Develop Better, Faster Clinical Trials with Best-in-Class Intelligence Solution
(Thomson Reuters ONE) -
Innovative intelligence solution provides real-time insights for more effective
drug trials
PHILADELPHIA, PA, December 5, 2012 - The IP & Science business of Thomson
Reuters, the world's leading provider of intelligent information for businesses
and professionals, today announced a preview of its newest intelligence
solution, Thomson Reuters Cortellis(TM) for Clinical Trials Intelligence.
Scheduled for release in early 2013, this capability will provide drug
development and clinical professionals with the critical information necessary
to evaluate market opportunities, identify potential barriers, and establish
informed decisions about clinical trial design and operations.
Cortellis for Clinical Trials Intelligence is the latest information solution
offered through Thomson Reuters Cortellis, the industry's premier Life Sciences
information delivery platform. It has the broadest remit of any clinical trials
database including a 45-year history of clinical outcomes, as well as the latest
market competitive activity from established and emerging markets such as China,
India and Brazil. It is the only solution that enables a customer to integrate
their proprietary research data with comprehensive clinical trials protocols and
outcomes, drug pipeline, biomarker, regulatory, financial and patent information
from Thomson Reuters. With its integrated analytics tools and visualizations,
users will have greater opportunities to maximize the value of clinical trial
content to inform internal strategy and decision-making.
"Cortellis for Clinical Trials Intelligence provides comprehensive clinical
trial protocols and outcomes with global reach and integrates with other key
intelligence areas - such as patents and literature - to allow for the broadest
possible perspectives and actionable insights," said Jon Brett-Harris, executive
vice president at Thomson Reuters. "However, it is not just an information web
portal. We are also providing multiple delivery options, such as dynamic real-
time visualizations, iPad support and application programming interfaces to
assist our customers in integrating it with their existing knowledge platforms
and workflow solutions."
Cortellis for Clinical Trials Intelligence optimizes critical clinical trial
functions by equipping R&D strategists with knowledge that helps them discover
market opportunities and potential barriers. This solution enables efficient
searching for competing trials as well as identifying countries rich in target
populations. By empowering clinical development teams to better understand trial
design trends, Cortellis for Clinical Trials Intelligence allows them to design
better and faster trials, while enabling marketing teams to pinpoint likely
competitors.
The experts of Thomson Reuters' professional services also utilize Cortellis for
Clinical Trial Intelligence and the company's other intelligence solutions -
including translational medicine offerings and clinical development and
portfolio strategy benchmarking - to support specific customer projects. Thomson
Reuters has more than 15 years of experience supporting clinical development in
the optimization of global clinical performance metrics, analysis and trending
through its business, CMR International.
For more information on Cortellis, visit cortellis.thomsonreuters.com.
Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for
businesses and professionals. We combine industry expertise with innovative
technology to deliver critical information to leading decision makers in the
financial and risk, legal, tax and accounting, intellectual property and science
and media markets, powered by the world's most trusted news organization. With
headquarters in New York and major operations in London and Eagan, Minnesota,
Thomson Reuters employs approximately 60,000 people and operates in over 100
countries. For more information, go to www.thomsonreuters.com.
CONTACTS
Jen Breen
Thomson Reuters
+1 215 823 1791
jennifer.breen(at)thomsonreuters.com
Abbey Anderson
Thomson Reuters
+1 215 823 1894
abbey.anderson(at)thomsonreuters.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Thomson Reuters Corporation via Thomson Reuters ONE
[HUG#1662592]
Unternehmensinformation / Kurzprofil:
Datum: 05.12.2012 - 14:00 Uhr
Sprache: Deutsch
News-ID 209983
Anzahl Zeichen: 5257
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 214 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Thomson Reuters Corporation: Thomson Reuters Empowers Drug Development and Clinical Professionals to Develop Better, Faster Clinical Trials with Best-in-Class Intelligence Solution"
steht unter der journalistisch-redaktionellen Verantwortung von
Thomson Reuters Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
